Search
Bithionol
go.drugbank.com/drugs/DB04813ApprovedWithdrawnApprovals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
go.drugbank.com/drugs/DB15729InvestigationalAdipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells ...
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Ingenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnIngenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIn 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigational[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Benralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019]
Lefamulin
go.drugbank.com/drugs/DB12825Approved[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnIt was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and